Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PARN | O95453 | 1/20 | 0.45 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583099 | 0.90 | KDM4E (0.56) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL22800909 | 0.87 | BRD4 (0.47) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL16058255 | 0.85 | CNOT7 (0.58) | BRD4KMT2APOLBPARNCNOT7 | |
| SCHEMBL555843 | 0.85 | BRD4 (0.45) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL555209 | 0.82 | PDE1A (0.64) | MEN1KMT2ALMNAPOLBMAPK1 | |
| SCHEMBL556233 | 0.81 | BRD4 (0.82) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL22105714 | 0.81 | PDE4A (0.55) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL16027883 | 0.81 | KDM4E (0.52) | MEN1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL6722467 | 0.81 | PDE4A (0.60) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL554932 | 0.81 | BRD4 (0.81) | BRD4MEN1KMT2ABRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4233871-A2 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Eli Lilly and Company (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11161849-B2 | Inhibiting the transient receptor potential al ion channel | ELI LILLY AND COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200392136-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2020-12-17 | — | — | US | disclosed |
| CN-107082782-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限责任公司 | 2020-03-20 | — | — | CN | disclosed |
| EP-1953162-A1 | Xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1757606-A1 | Xanthinderivatives, preparation thereof and their use as medical agents | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1368349-B1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060247226-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | HIMMELSBACH FRANK | 2006-11-02 | — | — | US | disclosed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BRD4 3145/4885MEN1 3272/4885KMT2A 3433/4885 |
| US-11161849-B2 | Inhibiting the transient receptor potential al ion channel | TRPV1, TRPA1, TRPV2 | BRD4 3723/4885MEN1 4734/4885KMT2A 3727/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BRD4 3056/4885MEN1 2867/4885KMT2A 3439/4885 |
| US-20060247226-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | BRD4 3056/4885MEN1 2867/4885KMT2A 3439/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | BRD4 3072/4885MEN1 2331/4885KMT2A 4201/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | BRD4 3072/4885MEN1 2331/4885KMT2A 4201/4885 |
| US-20200392136-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | BRD4 3382/4885MEN1 4518/4885KMT2A 4009/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | BRD4 3072/4885MEN1 2331/4885KMT2A 4201/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BRD4 3145/4885MEN1 3272/4885KMT2A 3433/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | BRD4 3072/4885MEN1 2331/4885KMT2A 4201/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | BRD4 3499/4885MEN1 4235/4885KMT2A 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.